<DOC>
	<DOCNO>NCT00440531</DOCNO>
	<brief_summary>The purpose trial determine improvement immune response older adult 50 year age use modified process hepatitis B vaccine currently license hepatitis B vaccine ( RECOMBIVAX HB™ ) .</brief_summary>
	<brief_title>Study Recombinant Modified Process Hepatitis B Vaccine Older Adults ( V232-059 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female old adult great equal 50 year age Any adult history previous hepatitis B infection A history vaccination hepatitis B vaccine Recent ( &lt; 72 hour ) history febrile illness ( oral temperature =37.8ºC/=100.0ºF ) Known suspect hypersensitivity component RECOMBIVAX HB™ ENGERIXB™ ( e.g. , aluminum , yeast ) Recent administration ( within 3 month prior first injection study vaccine ) hepatitis B immune globulin ( HBIG ) , serum immune globulin , bloodderived product Receipt license inactivated vaccine within 14 day prior first injection study vaccine Receipt license live virus vaccine within 30 day prior injection study vaccine Receipt investigational drug investigational vaccine within 3 month prior first injection study vaccine Known suspect impairment immunologic function recent use immunomodulatory medication ( e.g. , systemic corticosteroid ) . Does include topical inhaled steroid Pregnant woman , nurse mother , woman plan become pregnant within study period Any condition , opinion investigator , might interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>